Streptococcus mutans is the primary agent of dental cavities, in large part due to its ability to adhere to teeth and create a molecular scaffold of glucan polysaccharides on the tooth surface. Disrupting the architecture of S. mutans biofilms could help undermine the establishment of biofilm communities that cause cavities and tooth decay. Here we present a synthetic peptide P1, derived from a tick antifreeze protein, which significantly reduces S. mutans biofilm formation. Incubating cells with this peptide decreased biofilm biomass by approximately 75% in both a crystal violet microplate assay and an in vitro tooth model using saliva-coated hydroxyapatite discs. Bacteria treated with peptide P1 formed irregular biofilms with disconnected aggregates of cells and exopolymeric matrix that readily detached from surfaces. Peptide P1 can bind directly to S. mutans cells but does not possess bactericidal activity. Anti-biofilm activity was correlated with peptide aggregation and β-sheet formation in solution, and alternative synthetic peptides of different lengths or charge distribution did not inhibit biofilms. This antibiofilm peptide interferes with S. mutans biofilm formation and architecture, and may have future applications in preventing bacterial buildup on teeth.
INTRODUCTION
The ability of oral streptococci to establish biofilm growth on the surface of teeth is crucial to the formation of dental plaque and dental cavities. Streptococcus mutans in particular adheres to teeth and utilizes dietary sucrose to synthesize extracellular insoluble glucans that can serve as scaffolding for other microbes to colonize (Koo et al., 2013) . Tooth decay ensues when S. mutans and other microbes residing within the plaque biofilm produce acids that erode enamel. Along with the exopolysaccharides glucan and dextran, the composition of S. mutans biofilms has been described in detail (Klein et al., 2015) , and contains adhesin proteins and extracellular DNA (eDNA) (Liao et al., 2014) . Biofilm three-dimensional structure is established when microcolonies of S. mutans attached to a substrate multiply and then grow vertically, connecting with one another via the extracellular polymers. Throughout the biofilm matrix, water channels transport nutrients and signaling molecules to the cells (Donlan and Costerton, 2002) . This 3D architecture facilitates creation of low-pH microhabitats for oral microbes (Xiao et al., 2012) . The presence of and interplay between these molecular polymers, and the water channels, contribute to the stability of the network of the biofilm matrix that supports the cells. Interfering with S. mutans biofilm architecture may help prevent formation of oral biofilms that lead to dental caries.
Anti-biofilm molecules have been described with diverse mechanisms of action, such as: inhibiting bacterial adhesion, disrupting intercellular communication, and otherwise dispersing or preventing the establishment of biofilms (Bjarnsholt et al., 2013; Rendueles et al., 2013; de la Fuente-Núñez et al., 2014) . In contrast to antimicrobial peptides, which are important tools to combat oral pathogens (Chen et al., 2014; Ding et al., 2014) , some anti-biofilm agents do not directly kill bacteria, but instead interfere with their biofilm-forming capacity. Without the protective assemblage of the biofilm matrix, bacterial cells are more readily accessible and susceptible to antibiotics or disinfectants (Basak et al., 2013; Otter et al., 2015) . Since early biofilm establishment by oral streptococci often precedes the attachment of other oral pathogens, inhibiting these biofilms may help prevent further disease . Anti-biofilm molecules with activity against S. mutans and other oral streptococci include natural products such as alpha-mangostin (Thi et al., 2014) , salivary mucin glycoprotein (Frenkel and Ribbeck, 2015) , polysaccharide-degrading enzymes (Otsuka et al., 2015) , MPC-polymers (Hirota et al., 2011) , and small molecules that antagonize glucosyltransferases (Chen et al., 2015) .
Synthetic peptides represent a promising class of antibiofilm molecules, with activity against a variety of pathogens (Di Luca et al., 2015; Cardoso et al., 2016; de la FuenteNúñez et al., 2016; Pletzer and Hancock, 2016) . A cationic synthetic peptide, called P1, derived from the Ixodes tick antifreeze glycoprotein (IAFGP), demonstrates potent antibiofilm activity against Staphylococcus aureus, and confers an antivirulence effect in a catheter infection mouse model (Heisig et al., 2014) . Given its strong effect against S. aureus, we investigated the ability of peptide P1 to combat Streptococcus mutans biofilm formation. Antivirulence peptide P1 (distinct from the streptococcal adhesin protein that is called P1 or AgI/PAc) is a 24-amino acid synthetic peptide designed with repeated motifs found in the full IAFGP antifreeze glycoprotein sequence (Heisig et al., 2014) (Supplementary Table 2 ). Its sequence contains a positively charged N-terminal "PARKAR" motif followed by six "Ala-Ala-Thr" (AAT) repeats, a tripeptide repeat that is also characteristic of fish antifreeze glycoproteins (Neelakanta et al., 2010; Nagel et al., 2012) . Biofilm assays were conducted in vitro in tissue culture plates and on glass coverslips, and S. mutans biofilms were also tested on salivacoated hydroxyapatite (sHA) discs, which mimic the tooth surface. Here we demonstrate that peptide P1 disturbs the biofilm architecture in S. mutans, resulting in a drastic reduction of attached biofilm biomass.
MATERIALS AND METHODS

Peptide Synthesis and Bacterial Cultures
Peptides were synthesized by Genscript (Piscataway Township, NJ, USA) at >80% purity. Peptides P1 and sP1 matched previously published amino acid sequences (Heisig et al., 2014) and the alternative peptide sequences P0, P1-4, P1-7, and P17 were designed as variations of the P1 sequence (Figure 6 and Supplementary Table 2) . Lyophilized peptides were diluted in phosphate-buffered saline (PBS) to a stock concentration of 1 mg/ml and used immediately or frozen at −20 • C in 100 µl aliquots. Streptococci bacteria (Streptococcus mutans ATCC 25175, Streptococcus oralis ATCC 9811, and Streptococcus salivarius ATCC 13419), Gram-negative bacteria (Alcaligenes faecalis ATCC 8750, Enterobacter cloacae ATCC 23355, and Salmonella typhimurium ATCC 29629), and Grampositive bacterial strains (Abraham et al., 2017) were obtained from Yale University or Presque Isle Cultures (Erie, PA, USA). Bacterial cultures were maintained on Brain Heart Infusion (BHI) agar or broth (for streptococci), and Tryptic Soy agar or broth (TSA, TSB).
Biofilm Microplate Assay and Viability Assay
Biofilm assays were performed as previously described (Merritt et al., 2011) . Overnight cultures of S. mutans grown in BHI medium added to BHI+1% sucrose (BHI-S) at a concentration of 3-5 × 10 6 cfu/ml [by either a 1:100 dilution or normalizing to an optical density at 600 nm (OD 600 ) of 0.015]. The bacterial suspension was inoculated into quadruplicate wells of a 96-well tissue culture plate and P1 peptide or control sP1 peptide was added at a final concentration of 0.1 mg/ml (46 µM). Bacteria were incubated overnight at 37 • C with a CO 2 GasPak (BD, Franklin Lakes, NJ, USA). Crystal violet staining of biofilm plates was performed using standard protocols (Merritt et al., 2011) , as follows: Non-adherent cells were washed off by submerging the plate in water, and adherent cells were stained with 0.1% crystal violet, washed twice with water, dried, and resuspended in 33% acetic acid for 10 min. The absorbance of the resuspended solution was measured at 590 nm on a BioTek microplate reader. For the other Gram-negative and Gram-positive bacterial strains, the assay was identical except that the 96-well plates were incubated aerobically, and the biofilm culture media was TSB + 1% glucose for Gram-negatives, and BHI+1% glucose for Gram-positives.
To assess the bactericidal activity of P1 against S. mutans, overnight cultures of S. mutans were inoculated into 12-well or 24-well plates at a 1:100 dilution in BHI-S containing 0.1 mg/ml of P1 peptide, control sP1 peptide, or no peptide, and incubated overnight at 37 • C with a CO 2 GasPak. The S. mutans cells were collected in two ways: first, as a total (combined) sample, pooling all cells in both the supernatant (planktonic) and biofilm fraction; secondly, the supernatant (non-adherent) and biofilm fractions were separated and processed separately. For the combined sample, the attached biofilm cells were scraped off the bottom using a sterile 1.8 cm cell scraper, resuspended, and the entire contents of the well were transferred to a microcentrifuge tube. An additional 500 µl of PBS was added to the well and re-scraped to pick up any remaining adherent cells. For the separated fractions, the supernatant (containing planktonic bacteria) was pipetted off and transferred to a 1.5 ml tube, then 500 µl of PBS was added gently to the well to rinse off non-adherent cells, and transferred to the same "supernatant" tube. The biofilm cells were resuspended into 1 ml of PBS using a cell scraper, transferred to a new tube, and an additional 500 µl of PBS was added to the well and re-scraped to collect any remaining adherent cells. All samples (total, supernatant, or biofilm) resuspended in a total volume of 1.5 ml each, were briefly sonicated to break up cell clumps (10 pulses at 30-40% duty cycle), then serially diluted in PBS to 10 −7 , spread-plated on BHI agar, and incubated for 48-72 h at 37 • C with a CO 2 GasPak. After counting colonies, the number of colony-forming units (cfu/ml) was calculated for each sample.
Saliva-Coated Hydroxyapatite (sHA) Disc Experiments
The sHA disc procedure was carried out according to published protocols (Lemos et al., 2010) . We prepared authors' own clarified saliva for each experiment as follows: ∼10 mL of saliva was collected in a Falcon tube, stored on ice, and mixed with an equal volume of Adsorption Buffer (AB; 50 mM KCl, 1 mM potassium phosphate, 1 mM CaCl 2 , 0.1 mM MgCl 2 , pH 6.5), followed by the addition of 10 µl of 0.1 M phenylmethyl-sulfonyl fluoride (PMSF). The mixture was centrifuged at 5500 × g for 10 min at 4 • C. The supernatant (containing clarified whole saliva) was pipetted off carefully and filtered through a 0.22 µm PES low protein-binding filter (Steriflip, EMD Millipore, Billerica, MA, USA) and used immediately or stored at 4 • C. Sterile 5-mm diameter hydroxyapatite (HA) discs (3D Biotek, Bridgewater, NJ, USA) were aseptically placed into a sterile 15 ml tube containing 5-10 mL of clarified saliva and rotated at 37 • C for 1 h to coat discs with saliva. The sHA discs were then placed vertically in custom-made wire holders in pre-seeded wells of the 96-well culture plates. Triplicate wells were inoculated with a final volume of 200 µl of Streptococcus mutans in BHI-S (diluted to an OD 600 nm of 0.015), with either P1 or control sP1 peptides at 0.1 mg/ml. The plate was incubated at 37 • C with a CO 2 GasPak for 24 h. Discs were removed with sterile forceps, dip-washed three times in 0.89% NaCl, and placed in glass tubes containing 1 mL of 0.89% NaCl. The glass tubes were distributed in a custom Styrofoam rack and subjected to a 10-min ultrasonic bath. Following the ultrasonic bath, the detached cell suspension was transferred into microfuge tubes and sonicated (2x 5 pulses, on ice) to break up clumps of cells. Cells were serially diluted in PBS to 10 −5 , then plated on BHI agar and incubated at 37 • C with a CO 2 GasPak. After 48-72 h of incubation, S. mutans colonies were counted and cfu/disc was calculated.
Peptide Binding Assay and Immunoblot Analysis
Approximately 1.5 × 10 7 cells of S. mutans, from an overnight culture growing in BHI, were pelleted and washed in PBS and resuspended in 100 µL PBS. His-tagged P1 or sP1 peptides (GenScript, Piscataway Township, NJ, USA) were added to the cultures at 0.1 mg/mL. Bacteria-peptide mixtures were incubated for 10 min at 37 • C. Cells were pelleted by centrifugation, the supernatant (unbound fraction) was removed, and the pellet-associated (bound) fraction was washed with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) in PBS. The pellet (Associated) fraction and the supernatant (unbound) fraction were spotted directly onto a nitrocellulose membrane for immunoblot analysis. Bacterial bound (Associated) or unbound (Supernatant) peptide was detected using a monoclonal His-tagged antibody (Clontech, Mountain View, CA, USA). Cell wall bound fraction (Associated) versus unbound (Supernatant) bacterial fractions were distinguished using a polyclonal anti-Wheat Germ Agglutinin (WGA) (Vector Laboratories, Burlingame, CA, USA) antibody that detects bacterial peptidoglycan. Primary antibodies for both His and WGA were used at a 1:2000 dilution. Appropriate IR-conjugated LICOR secondary antibodies were used at a 1:5000 dilution and detected using the LI-COR Odyssey system (LI-COR, Lincoln, NE, USA). To normalize for any differences in reactivity between P1-His and sP1-His with the anti-His antibody, we quantified the bound signal intensity (Associated) and represented it as a percentage of the total signal (Associated + Supernatant):
.
Phase Contrast and Fluorescent Microscopy
Overnight cultures of S. mutans were inoculated at a 1:100 dilution in BHI-S with 0.1 mg/ml of P1 peptide or control sP1 peptide. Biofilms were formed either on coverslips in 6-well plates, or directly on the surface of 12-well or 24-well tissue culture plates (Corning, Corning, NY, USA). Bacteria were incubated overnight at 37 • C in containers with a CO 2 GasPak. Biofilm cultures and peptides in solution in tissue culture plates were viewed with phase contrast microscopy using a Zeiss Axio Vert.A1 microscope. For eDNA staining, a Miami Orange DNAbinding fluorescent probe (Kerafast, Boston, MA, USA) was used at a 1:200 dilution in the well, and viewed with a TRITC fluorescent filter. Images were captured using either a mounted camera with SPOT imaging software (SPOT Imaging, Sterling Heights, MI, USA) or an iPhone camera (Apple, Cupertino, CA, USA) mounted to the eyepiece of the microscope with a MiPlatform (Scientific Device Laboratory). Scale bars were calibrated using a stage micrometer.
Scanning Electron Microscopy (SEM)
S. mutans was inoculated at a 1:100 dilution into 500 µl of BHI-S in a 12-well tissue culture plate, with glass coverslips or silicon wafers aseptically placed at the bottom to allow for biofilm formation. Peptide P1 at 0.1 mg/ml was added to half of the samples, and the other half contained 0.1 mg/ml control peptide sP1. After 24 h of incubation with CO 2 at 37 • C, the coverslips and wafers were gently rinsed twice in 0.12 M phosphate buffer for 10 min. Coverslips/wafers were suspended for 1 h in a fixative solution containing 1.5% glutaraldehyde and 1% formaldehyde in 0.12 M phosphate buffer, followed by two rinses in 0.12 M phosphate buffer. Coverslips and wafers were then fixed in 1% OsO 4 in 0.12 M Phosphate for 30 min, followed by a di H 2 O rinse. Next, the coverslips/wafers went through FIGURE 1 | Anti-biofilm effect of peptide P1 in microplate assay and on sHA discs. (A) Peptide P1 reduces biofilm formation by Streptococcus mutans and oral streptococci in microplate assay. Cultures were incubated with peptide P1 and control peptide sP1 at 0.1 mg/ml final concentration. Biofilm biomass in microplate wells was stained with crystal violet (images below graph). Results are combined from three replicate experiments, and error bars indicate standard error of the mean. * * p < 0.01, * * * * p < 0.0001, Student's t-test. (B) Determination of minimum biofilm inhibitory concentration of peptide P1 against S. mutans. Biofilm inhibitory activity of P1 was measured by testing decreasing peptide concentrations in a microplate assay. Results were combined from three experiments, with biofilm biomass normalized to a percentage of the control. (C) Viability of S. mutans in the presence of peptide P1. Total S. mutans biomass (combined planktonic and biofilm cells from well) of cultures grown overnight in Brain Heart Infusion + 1% sucrose (BHI-S) without peptide or with 0.1 mg/ml P1 or sP1 was collected, diluted and plated, and cfu/ml was quantified for each condition. (D) Peptide P1 reduces Streptococcus mutans biofilm formation on saliva-coated hydroxyapatite (sHA) discs. Biofilm cfu/sHA disc showing combined results from three replicate experiments (total n = 9 discs/treatment). Peptide P1 and control peptide sP1 were used at 0.1 mg/ml final concentration. Error bars show standard error of the mean. * p < 0.05, using Student's t-test. (E) Custom-made wire holder holding the hydroxyapatite disc vertically in the well of a 96-well plate.
an ethanol dehydration process, suspended in the following concentrations of ethanol for 20 min each: 30, 50, 70, 95, 100% ethanol. Following the 100% ethanol, samples were moved to the critical point dryer in liquid CO 2 . After critical point drying, the coverslips/wafers were sputter coated with gold palladium in argon gas. Biofilm samples were imaged at the UConn BEML facility using an FEI Nova NanoSEM 450. Images were photographed at magnifications ranging from 500× to 50,000×, and the 3084× magnification was selected for bacterial chain length measurement. Twenty additional images from the P1 and Intensity is the signal of "associated" fraction as a percentage of total signal detected for each peptide [associated/(supernatant + associated)] * (100). Lower dotted line indicates the limit of detection by the LICOR Odyssey system. * p < 0.05, using Student's t-test.
FIGURE 3 | Peptide P1 activity against biofilms of Gram-negative bacteria. Biofilm biomass in microplate wells was stained with crystal violet (images below graph). Results are combined from three replicate experiments with cultures grown in TSB + 1% glucose, using peptides P1 and sP1 at 0.1 mg/ml final concentration. Error bars indicate standard error of the mean. control sP1 biofilms were taken at 3084×, and two representative images per treatment were used to estimate streptococcal chain length. Chains of cells with a clear beginning and end (30 chains per treatment group) were randomly selected and chain length was measured with ImageJ software (Schneider et al., 2012) .
Fourier Transform Infrared (FTIR) Spectroscopy
Synthetic peptides P1, P17, and sP1 were diluted to a concentration of 1 and 0.1 mg/ml in PBS. Aliquots of 8 µl per sample were dried as thin films directly on the ATR surface of a Bruker Alpha Platinum-ATR FTIR (Bruker Daltonics, Billerica, MA, USA). To scan for absorption peaks indicating the presence of β-sheets, spectra were recorded in the range of 1800-1500 cm −1 at a resolution of 2 cm −1 , with 50 scans per sample.
Statistical Analysis
Experiments were repeated independently at least three times, and one representative experiment or pooled data are shown. Data were analyzed using GraphPad Prism version 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Statistical significance was determined using Students t-test with Welch's correction (when comparing two groups) or OneWay ANOVA with Dunnett's or Sidak's multiple comparison post-test.
RESULTS
Antivirulence Peptide P1 Reduces S. mutans Biofilm in Microplates and on sHA Discs
The biofilm microplate assay using crystal violet staining is a rapid and convenient test for static biofilm formation. We cultured Streptococcus mutans cultures in BHI medium containing 1% sucrose, along with peptide P1 or a randomized scrambled peptide, sP1, a previously published negative control (Heisig et al., 2014) . Peptides were used at a final concentration of 0.1 mg/ml (46 µM). As shown in Figure 1 , when co-incubated with peptide P1 overnight, the biofilm biomass of Streptococcus mutans was reduced by approximately 80% compared to the control biofilms (sP1 peptide or no peptide) ( Figure 1A) . Likewise, incubation with P1 under the same conditions also reduced biofilm formation by two other oral streptococci, Streptococcus oralis and Streptococcus salivarius ( Figure 1A) . To determine the minimum effective concentration for biofilm inhibition of S. mutans, we tested decreasing concentrations of peptide P1. Significant anti-biofilm activity was observed at concentrations down to 25 µg/ml (Figure 1B) , however, 0.1 mg/ml gave consistent results and was used for all other experiments. Despite inhibiting biofilm formation, peptide P1 was not bactericidal against S. mutans, similar to the effect on S. aureus (Heisig et al., 2014) . Viability assays revealed a similar number of total colony-forming units present in control cultures and cultures incubated with P1, after dilution and plating of the entire contents of the tissue culture well (biofilm and non-adherent cells) ( Figure 1C) . As expected, when cells from the biofilm and non-adherent (supernatant) fractions were processed and quantified separately, there were ∼80% fewer cfu/ml in the biofilm-associated fraction of the P1-incubated S. mutans cultures compared to controls, and more cfu/ml in the non-adherent (supernatant) fraction (Supplementary Figure 1) .
To investigate the effect of peptide P1 on S. mutans biofilms in an in vitro tooth model, we prepared sHA discs, an established model that mimics tooth enamel coated with a salivary pellicle . The sHA discs were coated with clarified saliva using a standard method (Lemos et al., 2010) and incubated vertically for 24 h in handmade wire holders in 96-well plates (Figure 1E ) with S. mutans in BHI-S with peptide P1 or sP1. After incubation, attached biofilm bacteria were collected from the discs (by washing to remove loosely attached bacteria, then placed in tubes in an ultrasonic bath to detach biofilm bacteria from the discs). The detached biofilm bacterial suspension was sonicated to break up clumps of cells before plating onto BHI agar. When S. mutans was cultivated on the discs in the presence of P1, we observed a 70% decrease in the number of biofilm colony-forming units (cfu) per disc (7.7 × 10 6 cfu/disc) compared to the sP1 control (2.8 × 10 7 cfu/disc) ( Figure 1D ). We did not observe a significant difference in 48-h biofilms of S. mutans (data not shown).
Peptide Binding to S. mutans and Biofilm Inhibition of Other Bacteria
The full-length IAFGP protein, from which P1 was designed, was previously shown to bind to the cell surfaces of a range of bacteria, including both Gram-positive and Gram-negative species (Heisig et al., 2014) . Direct binding between both IAFGP and peptide P1 and cell wall peptidoglycan of S. aureus and Enterococcus faecalis was recently discovered (Abraham et al., 2017) . To establish whether peptide P1 can bind to S. mutans cells, we performed an immunoblot assay with His-tagged peptide P1 or sP1. The His-tagged peptides were incubated with a culture of S. mutans, then the cells were spun down, washed, and the cell-associated and unbound fractions were probed with anti-His antibody. As shown in Figure 2 , there was strong binding detected between His-P1 peptide with the cell-associated S. mutans fraction (antiHis, "Associated"), while only a trace amount of His-sP1 control peptide was detected bound to cells.
Since P1 peptide binds to S. mutans, and IAFGP binds to a range of bacteria (Heisig et al., 2014) , we wished to investigate the anti-biofilm effect of P1 against other bacteria. Recently, Abraham et al. (2017) reported that P1 had strong antibiofilm activity against biofilms of Gram-positive species, and no effect on Escherichia coli and P. aeruginosa biofilm formation (Abraham et al., 2017) . We tested the peptide against three additional biofilm-forming Gram-negative strains, A. faecalis, Enterobacter cloacae, and Salmonella typhimurium, and did not detect any statistically significant biofilm inhibition (Figure 3) . Supplementary Table 1 summarizes the findings from both studies on peptide P1 against the Gram-positive and Gramnegative bacteria tested thus far. Biofilms of Gram-positive species were reduced by 35-80%, and statistically significant reduction of biofilm by peptide P1 could be detected at concentrations as low as 5 µg/ml against S. oralis, and 10 µg/ml against S. aureus (Supplementary Table 1 ).
P1-Treated Biofilms have Disconnected Exopolymeric Matrix and Shorter Chains of Streptococci.
When S. mutans biofilms were allowed to form in the wells of 12-or 24-well tissue culture plates, cultures in the presence of peptide P1 exhibited large aggregates of cells and exopolymeric matrix, that detached readily from the surface (Figure 4 and Supplementary Figure 1) . Control sP1-treated biofilms were more uniform and firmly attached, with a continuous network of cells and exopolymeric matrix material (Figure 4 and Supplementary Figure 1) . To visualize eDNA in the biofilm matrix, we stained the total contents of the wells (adherent and suspended) with a fluorescent DNA-binding dye, and observed the same pattern of unevenly clumped matrix material with less attached to the surface of the well (Figure 4D) .
To further examine the altered biofilm structure of S. mutans treated with peptide P1, we performed SEM to look for differences in biofilm architecture and cell morphology at high resolution. At 500× magnification, there were fewer clumps of attached S. mutans microcolonies in the P1-treated sample ( Figure 5A) . At 3084× magnification, striking differences in streptococcal chain length were apparent between the samples, with the control cells forming significantly longer chains that were extensively interlinked ( Figure 5B ). We measured chain lengths using ImageJ software and found that the majority of streptococcal chains in the P1-incubated biofilm were less than 6 µm long, while chains of cells in the control group were more than twice as long, with most measured at 10-16 µm (Figures 5C,D) . The representative images in Figure 5B illustrate that cells of control biofilms form a more interconnected network, while cells incubated with P1 exist in discontinuous clumps.
Anti-Biofilm Activity Correlates with Peptide Sequence and Aggregation in Solution
To explore whether altering the sequence of P1 could enhance or eliminate its anti-biofilm activity, we designed modified peptide sequences and tested their anti-biofilm effect on S. mutans and S. aureus. Figure 6 lists the alternative peptide sequences with color-coded amino acid residues. Additional details including peptide molecular weights and net charges can be found in Supplementary Table 2. Peptide P0 directly matches the repeated sequence in the full length IAFGP protein (with 'PATAAT' instead of ' AATAAT'). Peptides P1-4 and P1-7 have fewer (4) or more (7) ' AAT' repeats, respectively, than P1. P17 is a different randomized scrambled peptide that lacks the proline residue. As seen in Figure 6 , each peptide had similar effects against both S. mutans and S. aureus at 0.1 mg/ml in the microplate crystal violet assay. None of the peptides with alterations in the ' AAT' repeats (P0, P1-4, or P1-7) reduced biofilm formation. The only variant peptide that showed some anti-biofilm activity was P17, which is a scrambled version of P1 that lacks the proline residue, and contains the three positively charged amino acids (R,R,K) at the C-terminus. Its effect was slightly less potent than that of P1. In addition to sharing the 24-aa length and +3 net charge at the terminus, P1 and P17 displayed another common property. These peptides form visible aggregates in BHI-S solution, even without bacteria present. Figure 7 shows microscopic images of each peptide in solution, with and without S. mutans bacteria, at 6 and 24 h of incubation. Figures 7A,C display the conspicuous self-aggregation of peptides P1 and P17 (arrows). After the bacterial biofilm forms, the wells treated with P1 and P17 display floating chunks of matrix material that appear to associate directly with the aggregated peptide.
The ability to self-aggregate indicates that P1 and P17 may have different secondary and tertiary structure than the other peptides, depending on the relative locations of proline and the charged and uncharged amino acids in each sequence (Figure 6) . We used Fourier transform infrared spectroscopy (FTIR) to assess the secondary structure of these two peptides compared to the negative control, sP1 (Haris and Chapman, 1995) . The assembly of P1 and P17 peptide monomers into higher order β-sheet structures were confirmed by the presence of a peaks at 1621 and 1695 cm −1 (Figure 8) , characteristic for antiparallel β-sheet formation (Cerf et al., 2009 ).
DISCUSSION
The synthetic peptide P1, designed from a tick antivirulence protein, strongly reduced biofilm formation by the oral pathogen Streptococcus mutans in an in vitro microplate assay and the sHA disc tooth model. Biofilm structure was drastically disrupted in S. mutans, with P1-incubated biofilms displaying sparse, irregular attachment, and chunks of matrix and cells that detached into the culture medium. In addition, the chains of streptococcal cells remaining attached in P1-treated biofilms were shorter and less interconnected than control cell chains, suggestive of a disturbance in the 3D structure of the biofilm. Peptide P1 formed aggregates in solution, and alternative peptides containing variations of the repeated ' AAT' sequences did not possess antibiofilm activity, with the exception of P17, a peptide that also aggregated and formed similar secondary structure to P1.
Combining this evidence with the direct binding observed between P1 and S. mutans cells, we propose a model in which peptide P1 binds to the bacterial surface and interferes with the proper secretion and/or intermolecular interaction of key extracellular polymers in the biofilm matrix, preventing strong attachment to the surface and connection between microcolonies in the biofilm . In biofilms of Gram-positive bacteria, interactions between exopolysaccharide (acidic, basic, or neutral), proteins, and the negatively charged eDNA or teichoic acids dictate the stability of the exopolymeric matrix (Otto, 2014) . In S. mutans, eDNA plays an important role in maintaining the mechanical stability of biofilms (Liao et al., 2014) , and interactions between eDNA in the biofilm matrix and the cation calcium (Ca 2+ ) were shown to enhance bacterial aggregation and biofilm stability in several species (Das et al., 2014) . As a positively charged peptide, P1 may affect interactions between the eDNA and exopolysaccharides, perturbing the typical bonding by altering the net charge at the surface of cells. Disrupted stability is evidenced by the floating chunks of cells and matrix that are readily washed away, rather than firmly attached to the substrate as intact biofilm.
The binding of peptide P1 at the cell surface may also interfere with the secretion and cell wall attachment of components of the biofilm exopolymeric matrix. Antivirulence P1 peptide has recently been shown to bind to the D-ala residue of the pentapeptide of S. aureus peptidoglycan (Abraham et al., 2017) . Since S. mutans shares the same D-ala residue in its peptidoglycan pentapeptide, this could potentially be the location of binding between P1 and the cell surface of S. mutans. Microscopic evidence (fragmented matrix and shorter chain length) suggests possible defects in cell envelope processing, which could be a result of P1 altering the activity of peptidoglycan-binding enzymes such as autolysin or sortase. The sortase enzyme SrtA, which covalently links LPxTG motif-containing proteins to the cell wall, is critical for biofilm formation in S. mutans (Lévesque et al., 2005) . SrtA governs the appropriate cell surface localization of biofilm adhesion proteins (Oli et al., 2012) , and plays a role in regulating eDNA in S. mutans biofilms (Liao et al., 2014) . Glucosyltransferase enzymes secreted by S. mutans are important for early attachment and glucan synthesis , and their activity might be impacted by cell surface-bound peptide P1. The mode of anti-biofilm activity by P1, with effects against various Gram-positive biofilms (Supplementary Table 1 ), likely differs depending on the composition of the exopolymeric matrix and the key steps in biofilm maturation. However, the absence of P1 anti-biofilm activity against Gram-negative bacteria observed in this study (Figure 5) , and by Abraham et al. (2017) We propose that the peptide's secondary structure and selfaggregation are critical to its activity, because the anti-biofilm effect was lost with shorter or longer versions of P1 (peptides P1-4 and P1-7), or peptides lacking a positive net charge at one terminus (peptides sP1 and P0) (Figure 6 and Supplementary Table 2 ). The strongest anti-biofilm effect was correlated with visible peptide aggregation (Figure 7) and formation of antiparallel β-sheets (Figure 8) . Antiparallel β-sheets contribute to the quaternary structure of amyloid fibrils (Cerf et al., 2009) , and functional amyloid proteins are produced by many bacteria to perform different cellular functions (Blanco et al., 2012) . Amyloid structures are now recognized for playing key roles in stabilizing the exopolysaccharide matrix of biofilms of bacteria (Taglialegna et al., 2016a) , including S. mutans (Oli et al., 2012) and S. aureus (Taglialegna et al., 2016b) . In S. mutans, a major constituent of the S. mutans biofilm matrix was shown to be an amyloid-forming protein (Oli et al., 2012) . This Ala-rich protein, known as "antigen I/II, PAc, or P1" (not to be confused with the synthetic peptide P1 used in this study), along with other cell-surface-localized amyloidogenic proteins, are important for biofilm stability (Oli et al., 2012; Besingi et al., 2017) . The Alarich, β-sheet forming properties of the synthetic P1 peptide may interfere with native amyloid-forming proteins. Aggregation and cell surface binding by P1 impede critical intermolecular interactions needed for proper S. mutans biofilm architecture, negatively impacting biofilm stability. In silico analyses of antimicrobial peptide sequences suggest that aggregation-prone regions are hotspots for the evolution of antimicrobial activity, when cationization in these regions results in amphipathic helical peptides (Torrent et al., 2011) . A compendium of biofilm-active antimicrobial peptides, with their effects on medically relevant species, can be found in the open-access "BaAMPs" database (Di Luca et al., 2015) . Amino acid composition analysis of peptides from this database revealed that biofilm inhibitory peptides preferentially contained positively charged residues (Arg and Lys) and that dipeptides such as "RK" were enriched in these peptides (Gupta et al., 2016) , suggesting the importance of the PARKAR motif in peptide P1. A broad-spectrum cationic synthetic peptide, Peptide 1018, which inhibits biofilms by blocking the bacterial signaling molecule (p)ppGpp (de la Fuente-Núñez et al., 2014) , was found to be effective in reducing multispecies oral biofilms (Wang et al., 2015) .
Since biofilm formation is highly dependent on environmental conditions and on the surface properties such as charge and hydrophobicity of the material (Song et al., 2015) , peptide P1 may be suitable for different formulations than existing antibiofilm molecules. Conclusions from this work can inform future rational design of synthetic anti-biofilm peptides. In addition to future application as an anti-biofilm catheter coating against S. aureus infection (Heisig et al., 2014) , it has potential to be used against oral biofilms on teeth or dental implant surfaces, alone or in combination with an antimicrobial such as chlorhexidine. FIGURE 8 | Secondary structure of peptides in solution using FTIR. Fourier transform infrared spectroscopy (FTIR) spectra of peptides P1, P17, and negative control sP1 at 1 mg/ml, with peaks at 1621 cm −1 indicative of β-sheet formation.
The synthetic peptide P1 is a promising candidate for further development as an anti-biofilm agent against streptococci or other Gram-positive pathogens.
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